A Possible Role for HMG-CoA Reductase Inhibitors and Its Association with <i>HMGCR</i> Genetic Variation in Parkinson’s Disease

Parkinson’s disease (PD) is the second most common neurodegenerative disease characterised by both motor- and non-motor symptoms, including cognitive impairment. The aetiopathogenesis of PD, as well as its protective and susceptibility factors, are still elusive. Neuroprotective effects of 3-hydroxy...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Anna Pierzchlińska, Marek Droździk, Monika Białecka
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	Parkinson’s disease statins HMG-CoA reductase inhibitors genetic polymorphisms neuroprotection Biology (General) QH301-705.5 Chemistry QD1-999
Acceso en línea:	https://doaj.org/article/0b1c93afe541436a8e32bbd5a9863666
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0b1c93afe541436a8e32bbd5a9863666
record_format	dspace
spelling	oai:doaj.org-article:0b1c93afe541436a8e32bbd5a98636662021-11-25T17:54:15ZA Possible Role for HMG-CoA Reductase Inhibitors and Its Association with <i>HMGCR</i> Genetic Variation in Parkinson’s Disease10.3390/ijms2222121981422-00671661-6596https://doaj.org/article/0b1c93afe541436a8e32bbd5a98636662021-11-01T00:00:00Zhttps://www.mdpi.com/1422-0067/22/22/12198https://doaj.org/toc/1661-6596https://doaj.org/toc/1422-0067Parkinson’s disease (PD) is the second most common neurodegenerative disease characterised by both motor- and non-motor symptoms, including cognitive impairment. The aetiopathogenesis of PD, as well as its protective and susceptibility factors, are still elusive. Neuroprotective effects of 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase inhibitors—statins—via both cholesterol-dependent and independent mechanisms have been shown in animal and cell culture models. However, the available data provide conflicting results on the role of statin treatment in PD patients. Moreover, cholesterol is a vital component for brain functions and may be considered as protective against PD. We present possible statin effects on PD under the hypothesis that they may depend on the HMG-CoA reductase gene (<i>HMGCR</i>) variability, such as haplotype 7, which was shown to affect cholesterol synthesis and statin treatment outcome, diminishing possible neuroprotection associated with HMG-CoA reductase inhibitors administration. Statins are among the most prescribed groups of drugs. Thus, it seems important to review the available data in the context of their possible neuroprotective effects in PD, and the HMG-CoA reductase gene’s genetic variability.Anna PierzchlińskaMarek DroździkMonika BiałeckaMDPI AGarticleParkinson’s diseasestatinsHMG-CoA reductase inhibitorsgenetic polymorphismsneuroprotectionBiology (General)QH301-705.5ChemistryQD1-999ENInternational Journal of Molecular Sciences, Vol 22, Iss 12198, p 12198 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Parkinson’s disease statins HMG-CoA reductase inhibitors genetic polymorphisms neuroprotection Biology (General) QH301-705.5 Chemistry QD1-999
spellingShingle	Parkinson’s disease statins HMG-CoA reductase inhibitors genetic polymorphisms neuroprotection Biology (General) QH301-705.5 Chemistry QD1-999 Anna Pierzchlińska Marek Droździk Monika Białecka A Possible Role for HMG-CoA Reductase Inhibitors and Its Association with <i>HMGCR</i> Genetic Variation in Parkinson’s Disease
description	Parkinson’s disease (PD) is the second most common neurodegenerative disease characterised by both motor- and non-motor symptoms, including cognitive impairment. The aetiopathogenesis of PD, as well as its protective and susceptibility factors, are still elusive. Neuroprotective effects of 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase inhibitors—statins—via both cholesterol-dependent and independent mechanisms have been shown in animal and cell culture models. However, the available data provide conflicting results on the role of statin treatment in PD patients. Moreover, cholesterol is a vital component for brain functions and may be considered as protective against PD. We present possible statin effects on PD under the hypothesis that they may depend on the HMG-CoA reductase gene (<i>HMGCR</i>) variability, such as haplotype 7, which was shown to affect cholesterol synthesis and statin treatment outcome, diminishing possible neuroprotection associated with HMG-CoA reductase inhibitors administration. Statins are among the most prescribed groups of drugs. Thus, it seems important to review the available data in the context of their possible neuroprotective effects in PD, and the HMG-CoA reductase gene’s genetic variability.
format	article
author	Anna Pierzchlińska Marek Droździk Monika Białecka
author_facet	Anna Pierzchlińska Marek Droździk Monika Białecka
author_sort	Anna Pierzchlińska
title	A Possible Role for HMG-CoA Reductase Inhibitors and Its Association with <i>HMGCR</i> Genetic Variation in Parkinson’s Disease
title_short	A Possible Role for HMG-CoA Reductase Inhibitors and Its Association with <i>HMGCR</i> Genetic Variation in Parkinson’s Disease
title_full	A Possible Role for HMG-CoA Reductase Inhibitors and Its Association with <i>HMGCR</i> Genetic Variation in Parkinson’s Disease
title_fullStr	A Possible Role for HMG-CoA Reductase Inhibitors and Its Association with <i>HMGCR</i> Genetic Variation in Parkinson’s Disease
title_full_unstemmed	A Possible Role for HMG-CoA Reductase Inhibitors and Its Association with <i>HMGCR</i> Genetic Variation in Parkinson’s Disease
title_sort	possible role for hmg-coa reductase inhibitors and its association with <i>hmgcr</i> genetic variation in parkinson’s disease
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/0b1c93afe541436a8e32bbd5a9863666
work_keys_str_mv	AT annapierzchlinska apossibleroleforhmgcoareductaseinhibitorsanditsassociationwithihmgcrigeneticvariationinparkinsonsdisease AT marekdrozdzik apossibleroleforhmgcoareductaseinhibitorsanditsassociationwithihmgcrigeneticvariationinparkinsonsdisease AT monikabiałecka apossibleroleforhmgcoareductaseinhibitorsanditsassociationwithihmgcrigeneticvariationinparkinsonsdisease AT annapierzchlinska possibleroleforhmgcoareductaseinhibitorsanditsassociationwithihmgcrigeneticvariationinparkinsonsdisease AT marekdrozdzik possibleroleforhmgcoareductaseinhibitorsanditsassociationwithihmgcrigeneticvariationinparkinsonsdisease AT monikabiałecka possibleroleforhmgcoareductaseinhibitorsanditsassociationwithihmgcrigeneticvariationinparkinsonsdisease
_version_	1718411843611918336

A Possible Role for HMG-CoA Reductase Inhibitors and Its Association with <i>HMGCR</i> Genetic Variation in Parkinson’s Disease

Ejemplares similares